Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)
Launched by UNIVERSITY OF PENNSYLVANIA · May 9, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
**Trial Summary: Vessel Wall Enhancement in Giant Cell Arteritis**
This clinical trial is investigating how well magnetic resonance imaging (MRI) can help detect inflammation in the arteries that supply blood to the head, brain, and eyes in patients with Giant Cell Arteritis (GCA). GCA, also known as temporal arteritis, can cause serious symptoms like headaches, vision problems, and jaw pain. The study is currently looking for participants who either have a new diagnosis of GCA or are experiencing a relapse of their condition with new or worsening symptoms. To be eligible, participants should have symptoms related to GCA and must be within 14 days of starting or increasing treatment with steroid medications, like prednisone.
Participants in the trial will have an MRI to check for signs of inflammation in their arteries. It's important to know that people with certain medical conditions, such as having a pacemaker or severe kidney issues, may not be able to participate. Additionally, individuals who are pregnant, nursing, or have significant anxiety about being in small spaces (claustrophobia) are also excluded. By participating, individuals will have the opportunity to contribute to research that may improve understanding and treatment of GCA for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 50 years or older
- • First presentation of suspected GCA
- • New or worsening cranial manifestations within 4 weeks of enrollment concerning for active GCA
- • Elevated CRP greater than 1.0 mg/dl
- • Plan to undergo temporal artery biopsy or ultrasound for diagnosis
- Exclusion Criteria:
- * Contra-indication to receiving MRI including:
- • Implanted medical devices, pacemaker, and metallic foreign fragments inside body/orbits Known gadolinium allergy Women who are pregnant or nursing
- • Absence of cranial symptoms related to GCA (e.g., only large vessel GCA)
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Rennie Rhee, MD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported